India's government has established price controls for 35 newly included essential medicines, addressing long-standing supply chain disruptions. This regulatory intervention targets critical pharmaceutical molecules that have faced chronic shortages across the healthcare system. With an additional 45 medications awaiting approval, authorities aim to stabilize drug availability while controlling costs for vulnerable populations. The initiative represents a significant step toward ensuring equitable access to vital treatments and strengthening the nation's pharmaceutical infrastructure.

Summary auto-generated by AI from the original publisher's content. Editorial standards.